Verlingue, L. Et Al. 2024. Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma. eBioMedicine , vol.109 .

Verlingue, L., Italiano, A., Prenen, H., Guerra Alia, E. M., Tosi, D., Perets, R., ... Lugowska, I.(2024). Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma. eBioMedicine , vol.109.

Verlingue, Loic Et Al. "Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma," eBioMedicine , vol.109, 2024

Verlingue, Loic Et Al. "Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma." eBioMedicine , vol.109, 2024

Verlingue, L. Et Al. (2024) . "Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma." eBioMedicine , vol.109.

@article{article, author={Loic Verlingue Et Al. }, title={Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma}, journal={eBioMedicine}, year=2024}